Genome‐wide CRISPR screening using palbociclib‐sensitive and palbociclib‐resistant T47D cells (HR‐positive breast cancer cell line) also identified CDK7 as the top‐ranked essential gene associated with acquired resistance to CDK4/6 inhibition.[32] Combined treatments suppressed the activation of FOXM1, consequently impacting the downstream SREBP1‐regulated cholesterol biogenesis pathway (Figure 6E). This evidence concerns the gene CDK4 and breast carcinoma.